Cancer drug development in Europe: A selection of new agents under development at the European Drug Development Network

D. Lacombe, A. Butler-Smith, P. Therasse, P. Fumoleau, S. Burtles, H. Calvert, S. Marsoni, C. Sessa, J. Verweij

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

From may 99, three european leaders in anti-cancer drug development (EORTC, Cancer Research UK, SENDO) have got together to form a network of collaborating groups: the European Drug Development Network. The member organisations have all agreed to join their efforts in developing new drugs. They have acquired a great and efficient expertise in anticancer drug development covering all aspects from drug screening to refinement of trial methodology and translational research. In this paper, the most interesting drugs under development in each of the three organisations are being described and discussed.

Original languageEnglish
Pages (from-to)137-147
Number of pages11
JournalCancer Investigation
Volume21
Issue number1
DOIs
Publication statusPublished - 2003

Fingerprint

Pharmaceutical Preparations
Neoplasms
Preclinical Drug Evaluations
Translational Medical Research
Research

Keywords

  • Cancer research
  • Clinical trials
  • European Drug Development Network
  • New drugs

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Lacombe, D., Butler-Smith, A., Therasse, P., Fumoleau, P., Burtles, S., Calvert, H., ... Verweij, J. (2003). Cancer drug development in Europe: A selection of new agents under development at the European Drug Development Network. Cancer Investigation, 21(1), 137-147. https://doi.org/10.1081/CNV-120016408

Cancer drug development in Europe : A selection of new agents under development at the European Drug Development Network. / Lacombe, D.; Butler-Smith, A.; Therasse, P.; Fumoleau, P.; Burtles, S.; Calvert, H.; Marsoni, S.; Sessa, C.; Verweij, J.

In: Cancer Investigation, Vol. 21, No. 1, 2003, p. 137-147.

Research output: Contribution to journalArticle

Lacombe, D, Butler-Smith, A, Therasse, P, Fumoleau, P, Burtles, S, Calvert, H, Marsoni, S, Sessa, C & Verweij, J 2003, 'Cancer drug development in Europe: A selection of new agents under development at the European Drug Development Network', Cancer Investigation, vol. 21, no. 1, pp. 137-147. https://doi.org/10.1081/CNV-120016408
Lacombe, D. ; Butler-Smith, A. ; Therasse, P. ; Fumoleau, P. ; Burtles, S. ; Calvert, H. ; Marsoni, S. ; Sessa, C. ; Verweij, J. / Cancer drug development in Europe : A selection of new agents under development at the European Drug Development Network. In: Cancer Investigation. 2003 ; Vol. 21, No. 1. pp. 137-147.
@article{37879398b43e4c628f15b3532d620291,
title = "Cancer drug development in Europe: A selection of new agents under development at the European Drug Development Network",
abstract = "From may 99, three european leaders in anti-cancer drug development (EORTC, Cancer Research UK, SENDO) have got together to form a network of collaborating groups: the European Drug Development Network. The member organisations have all agreed to join their efforts in developing new drugs. They have acquired a great and efficient expertise in anticancer drug development covering all aspects from drug screening to refinement of trial methodology and translational research. In this paper, the most interesting drugs under development in each of the three organisations are being described and discussed.",
keywords = "Cancer research, Clinical trials, European Drug Development Network, New drugs",
author = "D. Lacombe and A. Butler-Smith and P. Therasse and P. Fumoleau and S. Burtles and H. Calvert and S. Marsoni and C. Sessa and J. Verweij",
year = "2003",
doi = "10.1081/CNV-120016408",
language = "English",
volume = "21",
pages = "137--147",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Cancer drug development in Europe

T2 - A selection of new agents under development at the European Drug Development Network

AU - Lacombe, D.

AU - Butler-Smith, A.

AU - Therasse, P.

AU - Fumoleau, P.

AU - Burtles, S.

AU - Calvert, H.

AU - Marsoni, S.

AU - Sessa, C.

AU - Verweij, J.

PY - 2003

Y1 - 2003

N2 - From may 99, three european leaders in anti-cancer drug development (EORTC, Cancer Research UK, SENDO) have got together to form a network of collaborating groups: the European Drug Development Network. The member organisations have all agreed to join their efforts in developing new drugs. They have acquired a great and efficient expertise in anticancer drug development covering all aspects from drug screening to refinement of trial methodology and translational research. In this paper, the most interesting drugs under development in each of the three organisations are being described and discussed.

AB - From may 99, three european leaders in anti-cancer drug development (EORTC, Cancer Research UK, SENDO) have got together to form a network of collaborating groups: the European Drug Development Network. The member organisations have all agreed to join their efforts in developing new drugs. They have acquired a great and efficient expertise in anticancer drug development covering all aspects from drug screening to refinement of trial methodology and translational research. In this paper, the most interesting drugs under development in each of the three organisations are being described and discussed.

KW - Cancer research

KW - Clinical trials

KW - European Drug Development Network

KW - New drugs

UR - http://www.scopus.com/inward/record.url?scp=0037217237&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037217237&partnerID=8YFLogxK

U2 - 10.1081/CNV-120016408

DO - 10.1081/CNV-120016408

M3 - Article

C2 - 12643015

AN - SCOPUS:0037217237

VL - 21

SP - 137

EP - 147

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 1

ER -